Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III SEQUOIA study of pegilodecakin in metastatic pancreatic cancer misses primary endpoint

Oct. 16, 2019

AL-S Pharma initiates phase I study of AP-101 in ALS

Oct. 16, 2019

Radiolabeled anti-CD37 monoclonal antibody shows promise in preclinical lymphoma, CLL studies

Oct. 16, 2019

Sanofi begins phase I/II study of SAR-439483 in LCA caused by GUCY2D mutations

Oct. 16, 2019

Aura updates data from phase Ib/II study of AU-011 in primary choroidal melanoma

Oct. 16, 2019

Principia Biopharma reports preliminary data from phase I/II trial of PRN-1008 in ITP

Oct. 16, 2019

Novavax begins pivotal trial of NanoFlu in older adults

Oct. 16, 2019

[212Pb]Rituximab treatment to overcome hematological toxicity in non-Hodgkin's lymphoma

Oct. 16, 2019

Pfizer identifies muscarinic acetylcholine M4 receptor agonists

Oct. 16, 2019

New eukaryotic translation initiation factor 2B activators patented by Denali Therapeutics

Oct. 16, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...